Virologic features of SARS-CoV-2 infection in children

Lael M. Yonker[1,2,3*], Julie Boucau[4*], James Regan[5], Manish C. Choudhary[3,5], Madeleine D. Burns[1], Nicola Young[1], Eva J. Farkas[1], Jameson P. Davis[1], Peter P. Moschovis[2,3], T. Bernard Kinane[2,3], Alessio Fasano[1,2,3], Anne M. Neilan[2,3,6], Jonathan Z. Li[3,5*], Amy K. Barczak[3,4,6*]

1. Massachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA
2. Massachusetts General Hospital, Department of Pediatrics, Boston, MA, USA
3. Harvard Medical School, Boston, MA, USA
4. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
5. Brigham and Women's Hospital, Department of Medicine, Boston, MA, USA
6. Massachusetts General Hospital, Department of Medicine, Boston, MA, USA

*Authors contributed equally

Correspondence:

Lael Yonker: Massachusetts General Hospital, 55 Fruit St, Jackson 14, Boston, MA 02114. 617-724-2890. Lyonker@mgh.harvard.edu

Word count abstract: 200

Word count main text: 2894

Abstract

Background: Data on pediatric COVID-19 has lagged behind adults throughout the pandemic. An understanding of SARS-CoV-2 viral dynamics in children would enable data-driven public health guidance.

Methods: Respiratory swabs were collected from children with COVID-19. Viral load was quantified by RT-PCR; viral culture was assessed by direct observation of cytopathic effects and semiquantitative viral titers. Correlations with age, symptom duration, and disease severity were analyzed. SARS-CoV-2 whole genome sequences were compared with contemporaneous sequences.

Results: 110 children with COVID-19 (median age 10 years, range 2 weeks-21 years) were included in this study. Age did not impact SARS-CoV-2 viral load. Children were most infectious within the first five days of illness, and severe disease did not correlate with increased viral loads. Pediatric SARS-CoV-2 sequences were representative of those in the community and novel variants were identified.

Conclusions: Symptomatic and asymptomatic children can carry high quantities of live, replicating SARS-CoV-2, creating a potential reservoir for transmission and evolution of genetic variants. As guidance around social distancing and masking evolves following vaccine uptake in older populations, a clear understanding of SARS-CoV-2 infection dynamics in children is critical for rational development of public health policies and vaccination strategies to mitigate the impact of COVID-19.

Keywords: SARS-CoV-2, Pediatric COVID-19, Viral dynamics

Background

Since the SARS-CoV-2 virus ignited the COVID-19 global pandemic, the impact of the virus on children and the role that children play in this pandemic has been understudied. Initially, epidemiology reports suggested that children may have been relatively spared from infection, however, as COVID-19 testing became more available, it has been increasingly recognized that children can be infected with SARS-CoV-2 at rates comparable to adults [1, 2]. To date, over 4.1 million children in the Unites States have been reported as testing positive for COVID-19 [3]. Since the winter of 2020-2021, children under 19 years of age have represented one of the age groups with the highest rates of infection [4], which likely reflects a combination of increased number of infections among children plus increased vaccination rates amongst adults. Most children generally have milder symptoms when infected with SARS-CoV-2 [5], although a small subset of individuals develop severe disease. In the US, over 16,000 children have been hospitalized for acute COVID-19 with over 300 deaths reported[3]. A baseline understanding of the viral characteristics of SARS-CoV-2 infection in children is a necessary prerequisite to understanding the pathogenesis of severe presentations of COVID-19 [6].

At a population perspective, the role that children play in viral transmission remains poorly understood. Epidemiologic studies suggest that children exhibit lower transmission rates than adults [7], however, these findings are potentially confounded by higher rates of asymptomatic or pauci-symptomatic infection in children, increased social isolation by children early in the pandemic, and reduced COVID-19 testing in children. To date, one small study demonstrated that live virus can be cultured from children [8]. However, the types of systematic studies that have informed our understanding of the viral dynamics of SARS-CoV-2 in adult populations [9-11] have not similarly been carried out in children. As vaccination has become available for adults and adolescents in many places in the world and our understanding of transmission dynamics have evolved, masking and distancing policies are being relaxed[12]. Policy changes

have necessarily been made despite the paucity of data providing insight into the role that pediatric disease might play in ongoing transmission. As viral variants that enhance the potential for transmission and/or reduce vaccine efficacy emerge [13-15], the importance of identifying potential reservoirs of viral replication and transmission has been brought into the spotlight. Defining the virologic features of SARS-CoV-2 infection in children and the potential for children to transmit virus will facilitate rational public health decision-making for pediatric populations.

In this work, we sought to define fundamental virologic features of SARS-CoV-2 in a pediatric population across a range of disease severity. We analyzed respiratory swabs from children presenting to urgent care clinics or the hospital with symptomatic and asymptomatic COVID-19 infection. Clinical factors, such as age, COVID-19 risk factors, and disease severity were compared with viral features including SARS-CoV-2 viral load, isolation of replication-competent virus, and whole viral sequencing. Our data indicate that age, from infancy through adulthood, is not a predictor of viral infection dynamics, and that children of all ages can have high SARS-CoV-2 viral loads of replication-competent virus, including variants, displaying comparable dynamics to those seen in adults.

Methods

Sample collection

Infants, children and adolescents ≤21 years of age presenting to Massachusetts General Hospital urgent care clinics or the hospital with either symptoms concerning for or known exposure to COVID-19 (4/2020-4/2021) were prospectively offered enrollment in the Institutional Review Board-approved MGH Pediatric COVID-19 Biorepository (IRB # 2020P000955) [16]. After informed consent, and assent when appropriate, was obtained verbally, a research-designated swab of the nasopharynx, oropharynx and/or anterior nares was obtained and placed in phosphate buffered saline. Samples were aliquoted and stored at -80°C. Samples

98 from patients who tested positive for COVID-19 on clinical SARS-CoV-2 RT-PCR testing were
99 analyzed. Nasal samples from adults hospitalized with acute COVID-19 [10] (4/2020-8/2020;
100 enrolled in Institutional Review Board-approved MGH COVID-19 Biorepository, IRB #
101 2020P000804) with duration of symptoms equal to the hospitalized pediatric cohort were
102 selected for comparative studies.
103
104 **Clinical data collection**
105 Demographic and clinical factors were recorded through a combination of manual chart reviews
106 and data extraction from electronic health records (EHR), then collected in a REDCap database
107 [17] through the Partners Electronic Health Record Registry of Pediatric COVID-19 Disease
108 (IRB # 2020P003588). Trained reviewers collected demographics, SARS-CoV-2 risk factors,
109 comorbid conditions, medications, COVID-19 related symptoms, and laboratory tests. Outcome
110 of initial presentation to care, admission status, and complications of COVID-19 disease were
111 also extracted by manual review.
112
113 **SARS-CoV-2 viral load quantification**
114 Virions were pelleted from anterior nasal, oropharyngeal, and nasopharyngeal swab fluids by
115 centrifugation at approximately 21,000 x g for 2 hours at 4°C. RNA was extracted using Trizol-
116 LS (Thermofisher) according to the manufacturer's instructions. RNA was then concentrated by
117 isopropanol precipitation, and SARS-CoV-2 RNA was quantified using the CDC N1 primers and
118 probe [https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html] as
119 previously described [10]. As there was no significant difference in viral load from respiratory
120 secretions obtained from the anterior nares, nasopharynx or oropharynx of participants
121 (**Supplemental Figure 1**), samples were analyzed together, regardless of collection site.
122
123 **Viral Culture**

124 Vero-E6 cells (ATCC) were maintained in D10+ media [Dulbecco's modified Eagle's media
125 (DMEM) (Corning) supplemented with HEPES (Corning), 1X Penicillin/Streptomycin (Corning),
126 1X Glutamine (Glutamax, ThermoFisher Scientific) and 10% Fetal Bovine serum (FBS) (Sigma)]
127 in a humidified incubator at 37°C in 5% CO2. Vero-E6 cells were passaged every 3-4 days,
128 detached using Trypsin-EDTA (Fisher Scientific) and seeded at 150,000 cells per wells in 24
129 well plates for culture experiments and 20,000 cells per well in 96w plates the day before
130 inoculation for median tissue culture infectious dose (TCID50) experiments.
131
132 After thawing, each specimen was filtered through a Spin-X 0.45µm filter (Corning) at 10,000 x g
133 for 5min. 50µL of the supernatant was then diluted in 450µL of D^+ media [DMEM supplemented
134 with HEPES, 1X Penicillin/Streptomycin and 1X Glutamine]. The viral culture experiments were
135 performed as previously reported [18] with the following modifications: 100µL of the solution was
136 used to inoculate wells in a 24 well plate and 1mL of D_2^+ media [D+ media with 2% FBS] was
137 added to each well after 1 hour of incubation. The plates were then placed in a 5% CO2
138 incubator at 37°C. For TCID50 measurements conducted in parallel, 25µL of the Spin-X flow-
139 through was used to inoculate Vero-E6 cells in a 96 well plate in the presence of 5µg/mL of
140 polybrene (Santa Cruz Biotechnology) using 5-fold dilutions (5^{-1} to 5^{-6}) and 4 repeats for each
141 sample. The plates were centrifuged for 1 hour at 2,000 x g at 37°C before being placed in a 5%
142 CO2 incubator at 37°C. The SARS-CoV-2 isolate USA-WA1/2020 strain (BEI Resources) was
143 used as a positive control for CPE in both culture and TCID50 experiments.
144
145 Viral culture and TCID50 plates were observed at 3- and 6-days post-infection with a light
146 microscope and wells showing CPE were counted. The TCID50 titers were calculated using the
147 Spearman-Karber method. For the culture plates, the supernatant of the wells displaying CPE
148 was harvested 10-14 days post-infection and RNA was isolated using a QIAamp Viral RNA Mini
149 kit (QIAGEN) for confirmation of the viral sequence.

150

151 **SARS-CoV-2 sequencing**

152 cDNA synthesis was performed using Superscript IV reverse transcriptase (Invitrogen). Whole
153 viral amplification was performed with the Artic protocol using multiplexed primer pools designed
154 with Primal Scheme generating 400-bp tiling amplicons [19, 20]. PCR products were pooled and
155 Illumina library construction was performed using the Nextera XT Library Prep Kit (Illumina). The
156 comparison dataset included 183 representative contemporaneous SARS-CoV-2 genomes from
157 Massachusetts present in GISAID to assess for local clustering. Nucleotide sequence alignment
158 was performed with MAFFT (multiple alignment using fast Fourier transform) [21]. Best-fit
159 nucleotide substitution GTR+G+I was used for the datasets using model selection in IQ-Tree
160 followed by maximum likelihood phylogenetic tree construction using IQ-Tree web server with
161 1000-bootstrap replicates [22].

162

163 **Analysis**

164 All statistical analyses were performed using parametric comparisons in GraphPad Prism
165 (Version 9.1.1), including Pearson correlation, ANOVA with multiple comparisons, and unpaired
166 t test.

167

168 **Results**

169 **Clinical cohort**

170 One-hundred-ten children diagnosed with COVID-19 with a mean age of 10 years (range 0-21
171 years) were included in the study (**Table 1**). There were slightly more boys (56%) than girls
172 (44%) with SARS-CoV-2 infection included in our analyses. One third of the participants were
173 White (33%), 10% African American/Black, and 4% were Asian; one third (38%) reported their
174 ethnicity as Hispanic. Past medical history in children is reported in **Supplemental Table 1**.
175 Thirty children were asymptomatic but were identified as having COVID-19: twenty-six children

176 (27%) presented to urgent care/COVID-19 testing sites because of a COVID-19 exposure, while
177 four children (4%) were identified on routine screening during hospital admission. Eight (7%)
178 presented with COVID-19 symptoms but had no known COVID-19 contact. The majority of
179 participants with COVID-19 did not require hospitalization (72 children, 65%). Thirty-six children
180 (33%) were hospitalized with COVID-19, although only 18 children (16%) required supplemental
181 oxygen and/or invasive or non-invasive respiratory support (referred to as "moderate/severe
182 COVID-19").
183
184 **Age did not impact SARS-CoV-2 viral load or recovery of replication competent virus**
185 Age is a well-established risk factor for developing severe COVID-19. Accordingly,
186 asymptomatic patients were significantly younger than patients with mild disease, and pediatric
187 patients who were hospitalized with hypoxemia were significantly older than asymptomatic
188 children or children with mild disease (**Figure 1A**). However, viral load was not increased in
189 more severe disease: asymptomatic children and children with mild disease displayed
190 significantly higher viral loads than adults hospitalized with COVID-19 with comparable duration
191 of symptoms (less than 10 days) (**Figure 1B**). However, there were no differences in viral load
192 between pediatric patients hospitalized with moderate/severe disease and hospitalized adults of
193 similar duration of illness (**Figure 1B**) (Adult demographics are detailed in **Supplemental Table**
194 **2**).
195
196 The age of each infected child was analyzed to determine whether age impacted viral load.
197 There was no significant correlation of age with viral load (**Figure 1C**), nor were there significant
198 differences between ages when grouped by school levels: 0-4 years (infant through pre-school),
199 5-10 years (elementary school), 11-16 years (middle school), 17 and older (high school and
200 higher education) (ANOVA, P = 0.12) (**Figure 1D**). Thus, a child's age did not appear to impact

viral load: all children, from 2 weeks through 21 years of age, were equally capable of carrying a high viral load.

As SARS-CoV-2 RNA detection by RT-PCR does not specify whether replication-competent virus is being shed, we next sought to ascertain risk factors for shedding live virus by performing viral culture assays for recoverable SARS-CoV-2 in parallel with viral load testing. From the 110 participants, we collected 126 samples; live virus was cultured from 33 samples coming from 32 participants. Of note, eight of these children with culturable SARS-CoV-2 were asymptomatic. Higher viral load was significantly predictive of shedding of live virus (t test, $P < 0.0001$) (**Figure 2A**). Consistent with the results for viral load, age was not correlated with viral culture results; virus was recovered from children ages 1 month through 21 years (**Figure 2B**). Semi-quantitative assessment of the amount of virus shed by an individual participant was assessed by median tissue culture infectious dose (TCID50). TCID50 for culture-positive specimens correlated strongly with viral load (Pearson correlation $r = 0.7$, $P < 0.0001$) (**Figure 2C**) but did not correlate with age across all pediatric participants (**Figure 2D**).

Children with COVID-19 were most infectious within first five days of illness

To define the likely period of infectiousness in our pediatric population, we analyzed viral load, culturability, and TCID50 in comparison with duration of symptoms. Of note, duration of symptoms does not necessarily indicate duration of infection, as time infection was acquired cannot be confirmed. Consistent with prior reports in adults [9], viral loads in children were the highest earliest in the course of illness and declined over time after symptom onset (Pearson, $r = -0.4$, $P <0.001$) (**Figure 3A**). Viral load was highest in the first two days of symptoms, with significant decrease after 5 days of symptoms and further decline after 10 days of symptoms ($P < 0.0001$) (**Figure 3B**). Analysis of pediatric viral culture results demonstrated that children tested early after symptom onset were more likely to shed replication competent virus (P =

227 0.004) (**Figure 3C)**. Correspondingly, semi-quantitative assessment of infectious viral shedding
228 in children showed that the TCID50 was higher early after symptom onset and decreased over
229 time. When grouped by days of symptoms, children in days 0-2 of their symptoms had the
230 highest infectivity, while children with greater than six days of illness shed less virus (P = 0.004)
231 (**Figure 3D**).
232
233 We then sought to assess whether COVID-19 severity impacted the relationship between viral
234 load and age in pediatric cohorts of varying severity: asymptomatic, mildly symptomatic, and
235 moderate/severe pediatric COVID-19 patients. None of these COVID-19 severity groups
236 revealed any correlation of age with viral load (**Figure 4A**). Further, there were no differences in
237 viral clearance over the duration of illness, not only when comparing mild pediatric COVID-19
238 with moderate/severe COVID-19, but also when comparing pediatric COVID-19 with adults
239 hospitalized with COVID-19 (**Figure 4B**). Duration of symptoms did not affect the finding that
240 viral load does not correlate with age of the infected child (**Supplemental Figure 2**).
241
242 **Pediatric SARS-CoV-2 sequences were representative of those found in the community**
243 We successfully performed whole-viral sequencing of 57 respiratory samples from 54 children.
244 Phylogenetic analysis of these pediatric sequences with contemporaneous Massachusetts
245 sequences from GISAID showed that they were representative of the spectrum of sequences
246 found in the community (**Figure 5**). Notable variants identified in the pediatric samples included
247 four Alpha (B.1.1.7) and three Iota (B.1.526.2) variants. To validate our culture results on a
248 subset of culture-positive samples, we sequenced virus isolated from the supernatant from 8
249 positive samples. Sequences from the supernatant and respiratory specimens were identical in
250 7 cases and demonstrated only 1 nucleotide change in the last case.
251
252 **Discussion**

253 As the global COVID-19 pandemic took hold, infected older adults suffered high rates of
254 hospitalization and death while infected children typically experienced paucisymptomatic or
255 asymptomatic infection. While it is now clear that children can become infected with and
256 transmit SARS-CoV-2, viral dynamics in children have been understudied, and a full
257 understanding of the dynamics of infection in children is needed to inform public health policies
258 specific to the pediatric population. Here, we show that pediatric patients of all ages, from
259 infancy to young adulthood, can carry a high SARS-CoV-2 viral load in their upper airways,
260 particularly early in the course of infection, and an elevated viral load corresponds with high
261 levels of viable, replicating virus. Pediatric sequences were largely reflective of those found in
262 the general community and the presence of novel variants was identified.
263
264 Our findings have significant implications for both public health policy and the potential role of
265 universal vaccination of pediatric populations in fully curbing the COVID-19 pandemic. As
266 vaccination has rolled out in adult populations, public health policies are being adjusted to
267 account for changes in risk that result from vaccination. Our results emphasize the importance
268 of considering and clarifying how these policy changes relate to children. As adult populations
269 have been vaccinated, pediatric cases have represented a growing proportion of infections,
270 currently accounting for up to 25% of all COVID-19 cases across different regions of the United
271 States[3]. Our results suggest that the low rates of transmission in settings such as schools and
272 daycares cannot be attributed to low viral loads, low rates of viral shedding, or rapid clearance
273 of virus in younger patient populations. As changes in masking and distancing policies are
274 implemented for vaccinated adults, consideration of how and whether policies changes will be
275 applied for children will be critical for ongoing reduction of new COVID-19 cases.
276
277 Our results additionally suggest that pediatric populations have the potential to serve as a
278 community reservoir of actively replicating virus, with implications for both new waves of

infection and the evolution of viral variants. The duration of natural and vaccine-induced immunity for each vaccine in clinical use are not yet known. If a community reservoir of actively replicating virus is maintained and transmitted within unvaccinated pediatric populations, that population could then serve as a source of new infections as vaccine-induced immunity wanes in vaccinated adult populations. In addition, viral genomic variants were readily identified in the pediatric samples and these variants have the potential to impact viral transmission [23-25], disease severity [26, 27], and vaccine efficacy [28]. Ongoing viral replication within pediatric populations has the potential to serve as a source of existing and new viral variants that interfere with eradication efforts.

Our study has several limitations. First, the data collected here represent a single medical center and affiliated pediatric urgent care/COVID-19 screening clinics. However, these were amongst the few pediatric testing centers encompassing a large catchment area during the duration of this study, and patients enrolled spanned a wide range of symptoms. Additionally, many of these samples were collected early in the pandemic and SARS-CoV-2 variants of interest have shifted over time. Ongoing studies analyzing shifts in virologic features of SARS-CoV-2 infection in children alongside studies of infection in adults are needed to better understand the full reach of the COVID-19 pandemic.

Ultimately, our data suggest that although age is generally protective against severe disease, children, especially early in the infection course, carry high viral loads of SARS-CoV-2, which can include viral variants. Our results underline the importance of defining public health policy with viral dynamics in children in mind and of including pediatric populations in vaccine efforts aimed at eradication.

Acknowledgements:

The viral culture work was performed in the Ragon Institute BSL3 core, which is supported in part by the NIH-funded Harvard University Center for AIDS Research (P30 AI060354). This research was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), the Department of Pediatrics at Massachusetts General Hospital *for* Children (to LMY), the Massachusetts Consortium for Pathogen Readiness and a gift from Mark and Lisa Schwartz (to JZL).

Conflicts of Interest

The authors do not report any conflicts of interest.

316

317 1. Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): What Do We Know About
318 Children? A Systematic Review. Clin Infect Dis **2020**; 71:2469-79.
319 2. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-Related Differences
320 in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in
321 Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr **2020**;
322 174:902-3.
323 3. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-
324 covid-19-state-level-data-report/.
325 4. https://www.mass.gov/info-details/covid-19-response-reporting.
326 5. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric Severe Acute Respiratory Syndrome
327 Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. J Pediatr
328 **2020**; 227:45-52 e5.
329 6. Fialkowski A, Gernez Y, Arya P, Weinacht KG, Kinane TB, Yonker LM. Insight into the pediatric
330 and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-
331 CoV-2 infection. Pediatr Pulmonol **2020**.
332 7. Soriano-Arandes A, Gatell A, Serrano P, et al. Household SARS-CoV-2 transmission and
333 children: a network prospective study. Clin Infect Dis **2021**.
334 8. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in
335 Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis **2020**;
336 26:2494-7.
337 9. Weiss A, Jellingso M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-
338 19 patients: A systematic review and meta-analysis. EBioMedicine **2020**; 58:102916.
339 10. Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased
340 disease severity and mortality. Nat Commun **2020**; 11:5493.
341 11. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
342 with COVID-2019. Nature **2020**; 581:465-9.
343 12. https://www.cdc.gov/coronavirus/2019-ncov/index.html.
344 13. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine
345 against the B.1.351 Variant. N Engl J Med **2021**.
346 14. Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike
347 Variants. N Engl J Med **2021**.
348 15. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the
349 B.1.351 Variant. N Engl J Med **2021**.
350 16. Lima R, Gootkind EF, De la Flor D, et al. Establishment of a pediatric COVID-19 biorepository:
351 unique considerations and opportunities for studying the impact of the COVID-19 pandemic on
352 children. BMC Med Res Methodol **2020**; 20:228.
353 17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
354 capture (REDCap)--a metadata-driven methodology and workflow process for providing
355 translational research informatics support. J Biomed Inform **2009**; 42:377-81.
356 18. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an
357 Immunocompromised Host. N Engl J Med **2020**; 383:2291-3.

358 19. Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, et al. Introductions and early spread of
359 SARS-CoV-2 in the New York City area. Science **2020**; 369:297-301.
360 20. Quick J. nCoV-2019 sequencing protocol v1. Available at:
361 https://www.protocols.io/view/ncov-2019-sequencing-protocol-bbmuik6w.
362 21. Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence alignment,
363 interactive sequence choice and visualization. Brief Bioinform **2019**; 20:1160-6.
364 22. Trifinopoulos J, Nguyen LT, von Haeseler A, Minh BQ. W-IQ-TREE: a fast online phylogenetic
365 tool for maximum likelihood analysis. Nucleic Acids Res **2016**; 44:W232-5.
366 23. Zhou B, Thao TTN, Hoffmann D, et al. SARS-CoV-2 spike D614G change enhances replication
367 and transmission. Nature **2021**; 592:122-7.
368 24. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of
369 a spike L452R SARS-CoV-2 variant. Cell **2021**.
370 25. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2
371 lineage B.1.1.7 in England. Science **2021**; 372.
372 26. Davies NG, Jarvis CI, Group CC-W, et al. Increased mortality in community-tested cases of
373 SARS-CoV-2 lineage B.1.1.7. Nature **2021**; 593:270-4.
374 27. Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7,
375 B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill
376 **2021**; 26.
377 28. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape
378 neutralization by vaccine-induced humoral immunity. Cell **2021**; 184:2372-83 e9.
379

380

381 **Table 1**: Participant Demographics, past medical history, reason for presenting for SARS-CoV-2

382 RT-PCR testing, and disease severity of children with COVID-19 (n=110).

	COVID+ children (N=110)
Age, average (max, min)	10 (0,21)
Sex, n (%)	
Male	62 (56)
Female	48 (44)
Race, n (%)	
White	36 (33)
Black	11 (10)
Asian	4 (4)
Other	45 (41)
Ethnicity, n (%)	
Hispanic	42 (38)
Past Medical History, n (%)	
Obesity	28 (25)
Asthma	11 (10)
Other	39 (35)
Reason for presenting for COVID-19 testing, n (%)	
Asymptomatic, exposure	30 (27)
Symptomatic, exposure	72 (65)
Symptomatic, no exposure	8 (7)
COVID-19 Severity, n (%)	
Hospitalized	36 (33)
Supplemental oxygen	18 (16)
Outpatient	75 (68)

383

384

385

Figure 1: COVID-19 disease severity and SARS-CoV-2 viral load across age groups. **A.** Age of pediatric patients with SARS-CoV-2 infection, stratified by disease severity: asymptomatic (n=27), mild disease, outpatient (n=48), moderate/severe COVID-19, hospitalized (n=18). Analyzed by ordinary one-way ANOVA. **B.** SARS-CoV-2 viral load was quantified across a range of disease severities. Patients presenting with ≤10 days of symptoms were compared, including asymptomatic pediatric outpatients (n=27), mildly symptomatic pediatric outpatients (n=44), moderate/severe pediatric hospitalized patients with oxygen requirement (n=18), and moderate/severe adult hospitalized patients (n=29). Analyzed by ordinary one-way ANOVA. **C.** Viral load for each specimen (n=110) was determined by qPCR, plotted against participant age and analyzed by Pearson correlation. **D**. Viral load levels reported by school age group: 0-4 years old (yo)– infant through pre-school (n=32), 5-10yo – elementary school (n=23), 11-16yo – middle school (n=33), 17yo and over – high school and higher education (n=22). Analyzed by ordinary one-way ANOVA. Dotted lines depict limit of detection. * P<0.05, *** P<0.001, **** P< 0.0001, ns = not significant



401 **Figure 2**: SARS-CoV-2 culture results across age groups and viral load. **A-B**. Samples with
402 observable CPE (culture +) (n=31) or without observable CPE (culture -) (n=95) plotted against
403 viral load (**A**) and participant age (**B**) and compared using t test. **C-D.** Semiquantitative viral titer
404 expressed as TCID50/mL for culture positive samples plotted against corresponding viral load
405 (**C**) or participant age (**D**), Analyzed using Pearson correlation. Dotted line depicts limit of
406 detection. **** P < 0.0001
407



408
409

410 **Figure 3**: Culture positivity and duration of symptoms. **A**. Viral load for each specimen was
411 determined by qPCR and plotted against the duration of symptoms (in days). Analysis by
412 Pearson correlation**.** **B**. Viral load reported by binned duration of symptoms. Ordinary one-way
413 ANOVA used for analysis. **C.** Duration of symptoms for samples with observable CPE (culture
414 +, n=29) and without observable CPE (culture -, n=85). Analysis by t test. **D**. Semiquantitative
415 viral titer reported by binned duration of symptoms, analyzed by ordinary one-way ANOVA.
416 Dotted lines depict limit of detection. ** P < 0.01, **** P < 0.0001



417

418

419 **Figure 4**: Correlation of viral load with age and duration of illness based on disease severity.
420 **A**. Correlation of viral load and age, stratified by asymptomatic (n=30), mild outpatient (n=48)
421 and moderate/severe hospitalized (n=18) cohorts. **B.** Viral load of hospitalized adult (n=29),
422 hospitalized pediatric participants requiring respiratory support (n=18) and pediatric outpatients
423 with mild disease (n=48), plotted against duration of symptoms. Dotted lines depict limit of
424 detection.
425



426

427 **Figure 5**. Phylogenetic analysis of pediatric and community SARS-CoV-2 sequences. Maximum

428 likelihood tree generated from pediatric sequences (red) and 183 contemporaneous

429 Massachusetts sequences from GISAID.



430

431

432 **Supplemental Table 1**: Past medical history of children infected with SARS-CoV-2.
433

Past Medical History - Pediatric Patients
Acute recurrent pancreatitis
ADHD
Alopecia
Asthma
Autism
Cardiac conduction disorder
Chronic kidney disease
Coats Plus Syndrome
Crohn's disease
Cystic Fibrosis
Eczema
Epilepsy
G6PD Deficiency
Glutaric acidemia, type 1
Liver transplant
Mitochondrial complex 1 deficiency
Obesity
Obstructive sleep apnea
Prematurity
Sickle cell trait
Speech delay
Subglottic stenosis
Tracheobronchomalacia

434

435

436 **Supplemental Table 2**: Demographics, past medical history and disease severity of adults with

437 COVID-19 (n=29) included in analysis of SARS-CoV-2 viral load.

	COVID+ adults (n=29)
Age, average (max, min)	62 (26,93)
Sex, number (%)	
Male	13 (45)
Female	16 (55)
Race, number (%)	
White	20 (69)
Black	5 (17)
Asian	0 (0)
Other	4 (14)
Ethnicity, number (%)	
Hispanic	4 (14)
COVID-19 Severity	
Hospitalized, number (%)	21 (100)
Respiratory support	22 (78)
Outpatient, number (%)	0 (0)

438

439

440

441 **Supplemental Figure 1**: Viral load by sample collection location. Viral load of samples collected

442 from nasopharynx (n=60), anterior nares (n=47), or oropharynx (n=19) were compared and

443 analyzed by ordinary one-way ANOVA. ns = non-significant.

444



445

446

447 **Supplemental Figure 2**: Viral load plotted against pediatric patient age, for patients with 0-2

448 days symptoms (n=67), 3-5 days symptoms (n=30), and ≥6 days of symptoms (n=29). No

449 significant correlation in any grouping, when analyzed by Pearson correlation. Dotted lines

450 depict limit of detection. ns = not significant.



451